HomeIKT • NASDAQ
Inhibikase Therapeutics Inc
add
$2.01
0.99%
After Hours:(4.98%)-0.10
$1.91
Closed: May 16, 8:00:00 PM UTC-4 · USD · NASDAQ · Disclaimer
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 5.25M | 158.45% |
Net income | -13.68M | -194.19% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -15.75M | -229.79% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 93.18M | 855.76% |
Total assets | 94.28M | 751.83% |
Total liabilities | 8.55M | 99.25% |
Total equity | 85.73M | — |
Shares outstanding | 74.34M | — |
Price to book | 1.77 | — |
Return on assets | -40.86% | — |
Return on capital | -43.60% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -13.68M | -194.19% |
Cash from operations | -4.10M | -6.12% |
Cash from investing | 21.05M | 735.73% |
Cash from financing | — | — |
Net change in cash | 16.95M | 348.84% |
Free cash flow | -3.47M | -62.75% |
Previous close
$2.03
Day range
$1.96 - $2.07
Year range
$1.13 - $4.20
Market cap
149.43M USD
Avg Volume
127.61K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Founded
2008
Headquarters
Website
Employees
15
